MedPath

SINGAPORE CLINICAL RESEARCH INSTITUTE

πŸ‡ΈπŸ‡¬Singapore
Ownership
-
Established
2008-01-01
Employees
-
Market Cap
-
Website
http://www.scri.edu.sg/scri/

Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers

Phase 1
Conditions
Epithelial Cancers of the Lung, Breast, Ovary, Prostate and Colon
Interventions
Drug: Ad-sig-hMUC-1/ecdCD40L vector vaccine
First Posted Date
2014-05-16
Last Posted Date
2016-10-14
Lead Sponsor
Singapore Clinical Research Institute
Target Recruit Count
24
Registration Number
NCT02140996
Locations
πŸ‡ΈπŸ‡¬

National Cancer Centre Singapore, Singapore, Singapore

πŸ‡ΈπŸ‡¬

National Cancer Centre, Singapore, Singapore

The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes (T2DM)

Phase 4
Terminated
Conditions
Assess the Effects of a the 90-day Oral TS Study Regimen on PSA, IPSS, Haemoglobin and Haematocrit, and to Assess Adverse and Serious Adverse Events.
Interventions
First Posted Date
2012-01-18
Last Posted Date
2016-01-06
Lead Sponsor
Singapore Clinical Research Institute
Target Recruit Count
19
Registration Number
NCT01510847
Locations
πŸ‡ΈπŸ‡¬

EJ Tan Clinic & Surgery, Singapore, Singapore

πŸ‡ΈπŸ‡¬

Bukit Batok Medical Clinic, Singapore, Singapore

πŸ‡ΈπŸ‡¬

Frontier Medical Associates (Woodlands) Pte Ltd, Singapore, Singapore

and more 9 locations

Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)

Phase 1
Completed
Conditions
Hepatocellular Carcinoma
Interventions
Radiation: SIR-Spheres
First Posted Date
2008-07-10
Last Posted Date
2016-01-06
Lead Sponsor
Singapore Clinical Research Institute
Target Recruit Count
35
Registration Number
NCT00712790
Locations
πŸ‡°πŸ‡·

Seoul National University Bundang Hospital, Seoul, Korea, Republic of

πŸ‡ΈπŸ‡¬

Singapore General Hospital, Singapore, Singapore

πŸ‡ΈπŸ‡¬

National Cancer Centre, Singapore, Singapore

and more 2 locations
Β© Copyright 2025. All Rights Reserved by MedPath